The Journal of Korean Obstetrics and Gynecology (대한한방부인과학회지)

The Society of Korean Medicine Obstetrics and Gynecology (대한한방부인과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Gleditsiae Spina(GS) on Gene Expression of Human Breast Cancer Cells

조각자(皂角刺) 추출물이 인간 유래 유방암 세포의 유전자 발현에 미치는 영향

  • Ban, Hye-Ran (Dept. of Gynecology, College of Oriental Medicine, Dongshin University) ;
  • Cho, Seong-Hee (Dept. of Gynecology, College of Oriental Medicine, Dongshin University) ;
  • Park, Kyung-Mi (Dept. of Gynecology, College of Oriental Medicine, Dongshin University) ;
  • Yang, Seung-Jeong (Dept. of Gynecology, College of Oriental Medicine, Dongshin University)
  • 반혜란 (동신대학교 한의과 대학 한방부인과학 교실) ;
  • 조성희 (동신대학교 한의과 대학 한방부인과학 교실) ;
  • 박경미 (동신대학교 한의과 대학 한방부인과학 교실) ;
  • 양승정 (동신대학교 한의과 대학 한방부인과학 교실)
  • Published : 2009.05.29
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Gleditsiae spina (GS) has been used to treat patients with several diseases such as carbuncle, swelling and parasites. Recently GS is known to have anticancer activity in abdominal solid tumor, but the effects of GS on breast cancers is not clarified. For these reasons, we investigated effects of Gleditsiae spina (GS) on gene expression of human breast cancer cells. Methods: We investigated the effects of GS on proliferation of breast cancer cell line, MDA-MB-231. In addition, the genetic profile for the effect of GS on breast cancer cells was measured using microarray technique, and the functional analysis on these genes was conducted. Results: Total 1,434 genes were up-regulated and 2,483 genes down-regulated in the cells treated with GS. Genes induced or suppressed by GS were all mainly concerned with metabolic process, regulation of biological process and protein binding. The network of total protein interactions was measured using cytoscape program, and some key molecules that can be used for elucidation of therapeutical mechanism of medicine in future were identified. Conclusion: These results suggest possibility of GS as anti-cancer drug for breast cancer, and also suggest that related mechanisms are involved in regulation of intra-cellular metabolism in breast cancer cells.

Keywords

References

  1. 통계청. 2006년 사망원인통계연보(전국편). 2007.
  2. Perry S, Kowalski TL, Chang CH. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes. 2007;5:24. https://doi.org/10.1186/1477-7525-5-24
  3. Junichi Kurebayashi. Current Clinical Trials of Endocrine Therapy for Breast Cancer. Breast Cancer. 2007;14(2):200-214. https://doi.org/10.2325/jbcs.954
  4. 서연옥. 유방암 환자의 삶의 질 영향 요인. 대한간호학회지. 2007;37(4):459-66.
  5. 강진오. 유방암의 방사선 치료. 경희의학. 2005;21(1):37-42.
  6. Hind D, et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26):1-134.
  7. Jorgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist. 2007;12(4):397-405. https://doi.org/10.1634/theoncologist.12-4-397
  8. 김정진, 이경섭, 송병기. 유방종괴에 관한 문헌적 고찰, 대한한방부인과학회지, 1998;11(2):29-43.
  9. 전국한의과대학본초학교실. 본초학. 서울:영림사, 2000;440-1.
  10. 김인락. 조협과 皂角刺의 기원에 대한 연구. 대한본초학회지. 2006;21(1):44-9.
  11. 박용기, 강병수. 皂角刺의 소염작용에 대한 실험적 연구. 동국대학교 한의학연구소논문집. 1995;3:237-65.
  12. 권두한 등. 항바이러스 활성 식물자원 탐색. 한약작지. 2003;11(1):24-30.
  13. 박용기 등. 皂角刺의 항암작용에 대한 실험적 연구. 대한본초학회지. 1997;12:53-66.
  14. Roslev P, King GM. Application of a Tetrazolium Salt with a Water-Soluble Formazan as an Indicator of Viability in Respiring Bacteria. Appl Environ Microbiol. 1993 Sep;59(9):2891-2896.
  15. Florell SR, et al. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol. 2001;14(2):116-28. https://doi.org/10.1038/modpathol.3880267
  16. Weis S, et al. Quality control for microarray analysis of human brain samples: The impact of postmortem factors, RNA characteristics, and histopathology. J Neurosci Methods. 2007;165(2):198-209. https://doi.org/10.1016/j.jneumeth.2007.06.001
  17. Kwon KH, et al. Analysis of gene expression profiles in cholesteatoma using oligonucleotide microarray. Acta Otolaryngol. 2006;126(7):691-7. https://doi.org/10.1080/00016480500475633
  18. Zahurak M, et al. Pre-processing Agilent microarray data.BMC Bioinformatics. 2007;8:142. https://doi.org/10.1186/1471-2105-8-142
  19. Pavlícek A, Hrdá S, Flegr J. Free- Tree-freeware program for construction of phylogenetic trees on the basis of distance data and bootstrap/jackknife analysis of the tree robustness. Application in the RAPD analysis of genus Frenkelia. Folia Biol (Praha). 1999;45(3):97-9.
  20. Tracy GE. Breast cancer - the disease many women fear the most. S D J Med 2004;57(4):148.
  21. 임인숙. 유방암, 손상된 몸과 여성성의 위기감. 2006;22(4):6-46.
  22. 김종남, 권정혜. 유방암 환자를 위한 통합적 집단치료가 삶의 질과 면역 기능에 미치는 효과. 한국심리학회지. 2006;25(3):639-655.
  23. 김조자 등. 유방암 환자의 스트레스 대응능력 증진을 위한 심리사회적중재 효과. 대한간호학회지. 2006;36(1):169-78.
  24. 강선희, 전형진. 35세 이하 젊은 연령 유방암 환자의 예후 : 36세 이상 군과의 비교. 대한외과학회지. 2007;72(2):101-6.
  25. 정경아, 박경미, 조성희. 삼릉 추출물의 인간 유방암 세포성장억제 효과. 대한한방부인과학회지. 2006;19(1):166-77.
  26. 陳自明. 婦人良方大全, 臺北:集文書局, 1950;71-5.
  27. 龔廷賢. 萬病回春, 北京:人民衛生出版社, 1990;373.
  28. 張景岳. 景岳全書婦人規, 廣東:廣東科技出版社, 1986;286-9.
  29. 閭純璽. 胎産心法, 北京:人民衛生出版社, 1988;469-76.
  30. 羅元愷主編. 中醫婦科學, 北京:人民衛生出版社, 1988;44-50.
  31. 樓英. 醫學綱目卷19, 臺南:臺南北一出版社, 1973;44-50.
  32. 강서신의학원. 중약대사전(상), 서울: 성보사, 1980;1144-7.
  33. 양기호. 托裏消毒飮의 抗腫瘍 效果 및 免疫調節反應에 關한 硏究. 방제학회지. 1997;5(1):147-68.
  34. 이인철 등. 선방활명음의 항암 및 항산화효과 검증. 대한본초학회지. 2005;20(3):51-8.
  35. 남경수 등. 천궁이 유방암세포 증식, Nitric Oxide 생성 및 Ornithine Decarboxylase 활성에 미치는 영향. 생약학회지. 2004;35(4):283-7.
  36. Butt AJ, et al. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 2005;12(1):47-59. https://doi.org/10.1677/erc.1.00993
  37. Rowlands TM, et al. Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle. 2004;3(2):145-8.
  38. Ishii Y, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst. 2006;98(17):1238-47. https://doi.org/10.1093/jnci/djj334
  39. Myers ER, et al. Genomic tests for ovarian cancer detection and management. Evid Rep Technol Assess. 2006;145:1-100.
  40. James CR, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 2007;12(2):142-50. https://doi.org/10.1634/theoncologist.12-2-142
  41. McCoy ML, Mueller CR, Roskelley CD. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol. 2003;1:72. https://doi.org/10.1186/1477-7827-1-72
  42. Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res. 2003;5(1):45-52. https://doi.org/10.1186/bcr557
  43. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;7(12):937-48. https://doi.org/10.1038/nrc2054
  44. Wells PG, et al. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol Appl Pharmacol. 2005;207(2):354-66. https://doi.org/10.1016/j.taap.2005.01.061
  45. Maclean KH, Kastan MB, Cleveland JL. Atm deficiency affects both apoptosis and proliferation to augment Mycinduced lymphomagenesis. Mol Cancer Res. 2007;5(7):705-11. https://doi.org/10.1158/1541-7786.MCR-07-0058